33 C
Vientiane
Wednesday, April 30, 2025
spot_img
Home Blog Page 736

Hyundai ADM Unveils a “New Paradigm in Cancer Treatment” – Preclinical Study Shows Promise for Continuous Oral Chemotherapy with Lowered Side Effects Risks

SEOUL, South Korea, Jan. 22, 2025 /PRNewswire/ — Hyundai ADM Bio (Co-CEOs Taek-Sung Kim and Kwang-Hee Kim) announced the results of its preclinical study on the oral anti-cancer drug OTX-M, developed from the well-known injectable chemotherapy drug docetaxel, at the “Biotech Showcase 2025” held in San Francisco from January 13 to 15. The company introduced a “new paradigm in cancer treatment,” shifting from intravenous chemotherapy to patient-centered oral chemotherapy.

Technological Innovation: OTX-M Based on Organic-Inorganic Hybrid Drug Delivery Technology

OTX-M was developed using the patented organic-inorganic hybrid oral drug delivery technology of Hyundai ADM’s affiliated company, CNPharm. Unlike other oral anti-cancer drugs that failed to address drug-drug interaction issues, OTX-M enhances the bioavailability of docetaxel by more than 1,600 times without relying on metabolic inhibitors such as P-gp inhibitors or ritonavir. This breakthrough effectively resolves the challenge of low bioavailability while eliminating concerns about drug interactions.

Preclinical Study Results Identify the Optimal Regimen as One Daily Dose at a Moderate Dosage

The preclinical study systematically evaluated the effects of varying dosages (low, moderate, and high) and dosing frequencies, assessing anti-tumor efficacy and safety, as measured by weight changes.

Low doses administered twice daily showed a tumor inhibition rate of 61.4%, with minimal side effects and stable weight maintenance.

Moderate doses administered once daily achieved a tumor inhibition rate of 82.83%, demonstrating the best balance between anti-tumor efficacy and weight stability.

High doses administered four times per week achieved the highest tumor inhibition rate of 92.81%. However, weight loss and increased risk of side effects made this approach unsuitable for long-term cancer treatment.

The study demonstrated the dose-dependent anti-tumor efficacy of OTX-M, highlighting its excellent safety profile and low risk of side effects. A comprehensive analysis determined that a once-daily moderate dosage offers the optimal balance between efficacy and safety.

The Potential of OTX-M in the Global Cancer Treatment Market

OTX-M is expected to provide greater patient convenience and economic advantages, with the potential to rapidly replacing the current market dominated by injectable chemotherapy drugs. Research by Rutgers University and Chung-Ang University suggests that oral anti-cancer therapies can reduce treatment costs by 59.9% compared to injectable chemotherapies. This cost-effectiveness makes them an ideal solution for underdeveloped regions with limited medical resources. Additionally, the ability for patients to self-administer the medication at home, without the need for hospital visits, provides significant benefits for both patients and healthcare systems.

Global Industry Experts Highlight OTX-M’s Paradigm-Shifting Potential

A lead researcher from the new drug development division of a global pharmaceutical company, attending the Biotech Showcase commented, “The transition of taxane-based drugs, such as docetaxel and paclitaxel, into oral formulations has been a long-standing challenge that many pharmaceutical companies have attempted but failed to overcome. OTX-M represents the first example of successfully addressing both bioavailability and safety concerns. This technology could be a game-changer for cancer treatment and is expected to establish itself as an oral anti-cancer therapy in the global market following clinical trials in the United States.”

Hyundai ADM’s Commitment to Innovation in Cancer Treatment

Hyundai ADM’s CEO, Taek-Sung Kim, stated, “OTX-M is an innovative treatment that converts intravenous chemotherapy drugs into oral therapies with lowered side effects, significantly improving patient convenience and quality of life. We aim to usher in an era where cancer can be managed as a chronic condition, like diabetes or hypertension, and play a leading role in the global anti-cancer market.”

About Hyundai ADM Bio and Hyundai Bioscience

Hyundai ADM Bio is a subsidiary of Hyundai Bioscience, is a biotechnology company that develops anticancer drugs and also a Clinical Research Organization (CRO) service company in South Korea. ADM Korea Inc. is listed on the KOSDAQ market (symbol: 187660).

Hyundai Bioscience is a biotechnology company that develops new drugs based on its novel drug delivery system technologies to deliver active ingredients safely and efficiently to targeted areas of the human body. Founded in 2000, Hyundai Bioscience focuses on repurposing or expanding indications of existing drugs using its proprietary organic-inorganic hybrid technologies. Hyundai Bioscience is a public company listed on KOSDAQ (symbol: 048410) in South Korea.

Yuan Zhong Siu Launches New Products, Unlocking Good Luck this Chinese New Year


SINGAPORE – Media OutReach Newswire – 22 January 2025 – As 2025 approaches, Yuan Zhong Siu introduces its latest product collection, combining traditional wisdom with modern solutions. Featuring the 2025 Zodiac Bracelets and Tai Sui Safety Talismans, these products are thoughtfully designed to align with the year’s zodiac forecast, helping individuals enhance their luck, overcome challenges, and achieve balance in the upcoming year.

Crystal Bracelet & Tai Sui Safety Talisman
Crystal Bracelet & Tai Sui Safety Talisman

New Products Aligned with Zodiac Forecast Recommendations
Yuan Zhong Siu’s new product range is tailored to complement the zodiac recommendations, providing personalized support for career growth, relationship harmony, wealth enhancement, and protection against misfortune.

Chinese Zodiac Forecast 2025
The Chinese Zodiac forecast for 2025 reveals a year filled with opportunities and challenges, depending on each zodiac sign’s alignment with the year’s energies. Yuan Zhong Siu’s expert geomancers recommend specific strategies and tools to help each sign navigate the year ahead.

For more detailed zodiac forecast, visit https://yuanzhongsiu.com/zodiac-forecast/

2025 Zodiac Bracelets: Crystals for Luck and Balance
Each Zodiac Bracelet is crafted with natural crystals selected to address specific areas of life based on the zodiac forecast:

  • Wealth and Prosperity: Recommended for signs like the Goat, Dog, and Dragon, the Vegas Bracelet and Arthur the King Bracelet can amplify financial opportunities and sustain wealth luck in 2025.
  • Relationship Growth: Signs facing challenges in relationships, such as the Rabbit and Horse, can benefit from the Galaxy Bracelet, designed to enhance communication and emotional understanding.
  • Healing and Protection: The Ethereal Bracelet is ideal for those encountering obstacles in 2025, such as the Tiger, Snake, and Monkey, providing balance and shielding against misfortune.
  • Personal Growth: For individuals like the Rooster and Ox, who seek growth in career or personal life, the Dynasty Bracelet and Destiny Bracelet inspire self-discovery and goal achievement.


Tai Sui Safety Talisman: Protection Against Misfortune
For individuals born under zodiac signs clashing with Tai Sui in 2025 (Tiger, Snake, Monkey, and Pig), recommends carrying the Tai Sui Safety Talisman. This talisman is designed to mitigate effects of the Tai Sui clash, reduce obstacles and alleviate mental stress. It also supports both personal and professional development, while offering protection from potential misfortune. By carrying this talisman, individuals can pave the way for a luckier Chinese New Year and a successful 2025.

With Chinese New Year approaching, Yuan Zhong Siu is offering limited-time offers for these products. Visit their website here .

Hashtag: #crystalbracelet #safetytalisman #zodiacforecast2025 #yuanzhongsiu





The issuer is solely responsible for the content of this announcement.

About Yuan Zhong Siu

Yuan Zhong Siu, founded by Master Hillary Phang in 1989, offers Feng Shui products and services across Asia. The brand combines traditional Feng Shui principles with modern consultancy to help individuals address life’s challenges. Yuan Zhong Siu provides a range of products aimed at enhancing well-being, career, and financial growth. With retail outlets and offices in Singapore, the brand supports customers seeking solutions through Feng Shui practices.

ROHM’s Second-generation MUS-IC (TM) Series Audio DAC Chip for Hi-res Audio Playback with Exclusive HD Monaural Mode

– Delivers Authentic Listening Experience by Expressing Three Elements of Spatial Reverberation, Quietness, and Dynamic Range While Preserving Natural “Texture” of Musical Instruments –

KYOTO, Japan, Jan. 22, 2025 /PRNewswire/ — ROHM has developed a 32-bit D/A converter IC (DAC chip) and an evaluation board for flagship models in its MUS-IC (TM) series, optimized for high-resolution audio playback. DAC chips are key to audio equipment quality. With over 50 years of expertise, ROHM ensures superior sound design through high-fidelity processors and premium audio power ICs.

Product video: https://youtu.be/5VnsX4SSRQY?si=t_n5OzxBmLpliYZb

ROHM’s latest product builds upon the first-generation MUS-IC (TM) BD34301EKV, renowned for its sound quality and adoption in high-end models. The BD34302EKV inherits the core design concept behind ROHM’s DAC chip, which emphasizes natural flat sound. By integrating the three elements of spatial reverberation, quietness, and dynamic range from the MUS-IC (TM) series, it authentically reproduces the “texture” of musical instruments for an even more realistic audio experience.

Image: https://cdn.kyodonewsprwire.jp/prwfile/release/M106254/202501092652/_prw_PI1fl_39cYfY1W.jpg

By incorporating a new algorithm for data-weighted averaging (DWA), the BD34302EKV achieves a THD+N characteristic of -117dB (THD: -127dB), a key performance indicator that enhances sound quality by achieving a sound quality that conveys a realistic sense of texture. In addition, the signal-to-noise ratio (SNR) of 130dB provides noise performance befitting a flagship DAC chip, while a sampling frequency of up to 1,536kHz allows customers to fully leverage the high-precision calculations of their digital signal processors (DSPs).

Product image: https://cdn.kyodonewsprwire.jp/prwfile/release/M106254/202501092652/_prw_PI4fl_vtl1N22C.jpg

In monaural mode, which allocates one DAC chip per channel, ROHM’s proprietary HD (high definition) monaural mode contributes to smoother, more natural sound. As part of the MUS-IC (TM) series, uncompromising craftsmanship has been applied down to the smallest details. Based on years of expertise in sound quality design, the optimal bonding wire material for each terminal of the BD34302EKV was selected to accurately convey the natural “texture” of musical instruments. These features help create the ideal sound sought by high-end audio manufacturers.

Special page: https://micro.rohm.com/en/mus-ic/

*In this release, “DAC chip” differentiates the IC from the DAC in audio equipment.

*MUS-IC is a trademark or registered trademark of ROHM Co., Ltd.

Release: https://www.rohm.com/news-detail?news-title=2025-01-22_news_music&defaultGroupId=false

About ROHM: https://kyodonewsprwire.jp/attach/202501092652-O1-39CK07wm.pdf

Logo: https://cdn.kyodonewsprwire.jp/prwfile/release/M106254/202501092652/_prw_PI3fl_o748borj.jpg

Official website: https://www.rohm.com/

Automation Anywhere’s AI Agents Power PwC India’s Intelligent Spend Management Suite (ISMS)

DAVOS, Switzerland, Jan. 22, 2025 /PRNewswire/ — Automation Anywhere Inc.(AAI), the world’s leading Agentic Process Automation (APA) platform, and PwC India strengthened their partnership by integrating advanced Agentic AI capabilities from Automation Anywhere into PwC India’s proprietary Intelligent Spend Management Suite (ISMS).

PwC India’s Intelligent Spend Management Suite (ISMS) is an Agentic AI platform designed to transform the way businesses manage their spend and run their payable operations. This product leverages the power of  Generative AI agents which will now be powered by Automation Anywhere. This will give ISMS specific capabilities to drive intelligent buying decisions, execute touchless account payables and enhance critical outcomes.

This modular, Agentic AI platform allows API integrations with existing systems to greatly improve operational efficiency, transparency and insights for better decisions. 

In 2024, Automation Anywhere announced a strategic partnership with PwC India to develop Generative AI-driven solutions aimed at transforming key business operations. The integration of Automation Anywhere’s advanced Agentic AI capabilities into PwC India’s Intelligent Spend Management Suite (ISMS) marks a significant milestone in the collaboration.  

Commenting on the announcement with Automation Anywhere, Sanjeev Krishan, Chairperson, PwC in India said, “The integration of Automation Anywhere’s advanced Agentic AI capabilities into PwC India’s Intelligent Spend Management Suite represents a step forward in addressing some of the most pressing challenges faced by businesses today. By combining our deep industry insights, AI & Tech expertise and domain understanding with Automation Anywhere’s Agentic AI platform, we are empowering organizations across sectors to drive efficiency, enhance decision-making, and unlock greater value in their spend and payable operations.”

Joe Atkinson, PwC’s Global Chief AI Officer added, “Agentic AI is a step-change in the AI revolution, one that is going to play a significant role in the business model reinvention of enterprises globally. AI is starting to disrupt value chains across whole industries, and with ISMS value realization for businesses becomes real. I’m excited to see the collaboration between us and Automation Anywhere.”

“Our industry-leading Agentic Process Automation platform has the unparalleled ability to drive actions by solving real world customer problems with GenAI. We recognize PwC India’s market potential that will significantly increase the deployment of AI Agents aiding in a strategic long-term vision to deliver superior business outcomes for our customers,” said Ankur Kothari, Chief Operating Officer, Automation Anywhere.

Manpreet Singh Ahuja, Chief Digital Officer and Partner, PwC India said, “PwC India’s Intelligent Spend Management Suite which leverages Agentic AI, is an example of our commitment to move AI from experimentation to enterprise grade deployments. This product addresses a key business challenge: making payables management smarter and more efficient. Working with Automation anywhere, we will be able bring collective expertise of both enterprises to solve client challenges.”

Key features of PwC India’s Intelligent Spend Management Suite (ISMS) include:

  • Generative AI agents for advanced process insights, validation and executing actions
  • Modular design for seamless integration with existing systems
  • API-first architecture for faster implementation and scalability
  • Strong underlying layer of data, validations, and workflow implementations

The combined efforts of Automation Anywhere with PwC India is poised to develop breakthrough solutions that will revolutionize the way of working across several business verticals.

About Automation Anywhere Inc

Automation Anywhere is the world’s leading Agentic Process Automation (APA) Platform that puts AI to work across organizations. The company’s platform is powered with specialized AI, generative AI and offers process discovery, RPA, AI agents, end-to-end process orchestration, document processing and analytics, with a security and governance-first approach. Automation Anywhere empowers organizations worldwide to unleash productivity gains, improve customer experiences and create new revenue streams. The company is guided by its vision to fuel the future of work by unleashing human potential through Agentic AI-powered automation. Learn more at www.automationanywhere.com

About PwC

At PwC, our purpose is to build trust in society and solve important problems. We’re a network of firms in 152 countries with over 327,000 people who are committed to delivering quality in Assurance, Advisory and Tax services. Find out more and tell us what matters to you by visiting us at www.pwc.com.

PwC refers to the PwC network and/or one or more of its member firms, each of which is a separate legal entity. Please see www.pwc.com/structure for further details.

Anbio Biotechnology to Showcase Cutting-Edge Diagnostic Solutions at 2025 Medlab Middle East

DUBAI, UAE , Jan. 21, 2025 /PRNewswire/ — Anbio Biotechnology (“Anbio”), a global leader in in-vitro diagnostic technologies, is excited to announce its participation in the 2025 Medlab Middle East exhibition, taking place from 3rd to 6th February at the Dubai World Trade Centre. The event is one of the region’s largest and most important medical and laboratory equipment trade shows, bringing together leading manufacturers, distributors, and healthcare professionals from around the globe.

Anbio Biotechnology's booth Z1.H50 at 2025 Medlab Middle East
Anbio Biotechnology’s booth Z1.H50 at 2025 Medlab Middle East

Anbio Biotechnology will be showcasing a range of its latest Point-of-Care Testing (POCT) products at Booth Z1.H50. These products include:

  • Dry Chemiluminescence Immunoassay System (Dry CLIA)
  • Immunofluorescence System (FIA)
  • Dry Biochemistry System
  • Colloidal Gold Rapid Tests

The company’s participation aims to provide healthcare professionals, medical device distributors, and patients in the Middle East, Africa, and Europe with fast, reliable, and cost-effective in-vitro diagnostic solutions that enhance healthcare outcomes.

Anbio’s Featured Products at Medlab Middle East:

  • Dry Chemiluminescence Immunoassay System

The innovative dry chemiluminescence immunoassay system utilizes lyophilized reagents to enhance stability, reduce liquid reagent volume, and improve temperature resistance for room-temperature storage and transport. Compatible with nearly 70 reagents, it covers applications like coagulation, thrombosis, cancer markers, and hormone testing, ensuring reliable results across various clinical settings.

  • Immunofluorescence System

Ideal for rapid and precise detection, this immunofluorescence system is a powerful tool for Point-of-Care Testing (POCT). It supports 85 test parameters and is equipped with a built-in battery, allowing up to 8 hours of continuous testing without an external power source. Its versatility makes it suitable for various environments, including laboratories, ambulances, and pharmacies, ensuring reliable diagnostics wherever needed.

  • Dry Biochemistry System

The innovative dry biochemistry system ensures simplicity, efficiency, and reliability in various tests, particularly in emergency settings. It utilizes dry reagent strips, with one strip dedicated to each patient, and supports whole blood testing for most assays. The reagents can be stored and transported at room temperature. Offering quick and accurate biochemistry quantification, results are available in as little as 40 seconds, making it the ideal solution for fast-paced environments.

  • Colloidal Gold Rapid Tests

These tests provide a quick, easy-to-read, and reliable solution for detecting a variety of infections and conditions, offering fast results for better decision-making in patient care. With a wide range of available reagents, the system covers nearly 100 different test items, making it a cost-effective choice, particularly for large-scale screening.

About Medlab Middle East

Medlab Middle East is the region’s premier event for laboratory and medical professionals, providing access to a vast array of the latest innovations in diagnostics, laboratory management, and medical technology. With thousands of visitors and exhibitors from around the world, it serves as a vital platform for networking, collaboration, and learning about emerging trends in healthcare diagnostics.

Anbio Biotechnology’s innovative solutions at Medlab Middle East will demonstrate its commitment to advancing the future of diagnostic technology and improving healthcare delivery worldwide.

Visit us at Booth Z1.H50 at Medlab Middle East to learn more about our products and how they can transform your healthcare practices.

 

LG Energy Solution Ranked as the World’s 12th Most Sustainable Company, Number One Among Battery Manufacturers

  • Corporate Knights acknowledges LG Energy Solution in the World’s 100 Most Sustainable Corporations 2025 list, placing it in the top position among its industry peer group
  • Recognition in sustainable revenue and sustainable investment were the main drivers of the strong performance, as well as energy productivity and GHG (Greenhouse gas) productivity
  • Embracing responsibility as an industry leader, LG Energy Solution strives to bolster its own ESG management and pave the way to a sustainable battery ecosystem across the entire value chain, including indirect operations and suppliers

SEOUL, South Korea, Jan. 22, 2025 /PRNewswire/ — LG Energy Solution has ranked 12th on the list of 100 Most Sustainable Corporations in the World 2025 by Corporate Knights, marking its debut on the prestigious list. The company also secured the top position among its battery manufacturing peers.

Corporate Knights’ Global 100 is a global sustainability index that provides an annual ranking of the world’s most sustainable corporations with annual revenues of over 1 billion USD. This year’s evaluation examined 8,359 corporations, scoring companies based on 25 key performance indicators across areas such as sustainable revenue, sustainable investment, resource management, employee management, financial management, and supplier performance. A ranking on this list is widely considered a mark of distinction for ESG management excellence.

LG Energy Solution’s strong performance in the sustainable revenue and sustainable investment KPIs earned its recognition in the Global 100 assessment, meeting key criteria for ESG-conscious investors. The company received the highest possible scores in both areas, reflecting its core business of providing sustainable and reliable energy solutions and its significant investments in future growth engines.

Corporate Knights also highly rated LG Energy Solution’s energy productivity and GHG productivity, among other criteria.

LG Energy Solution is dedicated to strengthening its ESG standards and practices, demonstrating the company’s industry leadership. As such, the company has recently focused on preparations for stricter global regulations and ESG disclosure standards. Even before new international battery regulations, such as mandatory carbon footprint disclosure and battery passports, LG Energy Solution already adopted Life Cycle Assessment (LCA) in 2019 to evaluate the product impacts and transparently communicate with key stakeholders. LG Energy Solution aims to ensure the accuracy and credibility of LCA through third-party verification and Environmental Product Declaration (EPD) certifications, and the range of products covered by LCA and EPD continues to expand. In 2024, LCA covered battery cells with 83% of total capacity, and EPD certified battery cells with 60% of total capacity.

Furthermore, the company made substantial progress in social footprint management, reducing the potential for adverse human rights impacts by adopting a due diligence process to identify, prevent, mitigate, and address such issues. Enhancing its ESG governance, LG Energy Solution is committed to effectively managing emerging challenges and fostering an ESG-driven work culture.

In addition to reinforcing its own ESG management, the company is working to facilitate a sustainable battery ecosystem throughout its entire value chain by proactively supporting, engaging, and collaborating with its supply chain partners. Building on years of assessing and managing ESG risks in its Tier 1 suppliers, the company expanded these efforts in 2024, developing an IT management system that connects Tier-N suppliers for improved traceability and transparency. It plans to progressively broaden the scope of supply chain risk assessment, focusing on core raw material supply chains for critical regulatory compliance. To maintain transparency, LG Energy Solution published the ‘Supply Chain Sustainability Report’ this month, which provides information on its supply chain management system, strategies, and key achievements.

“We are honored that Corporate Knights has recognized our leadership in sustainability and ESG practices, naming us one of the world’s most sustainable companies,” said David Kim, CEO of LG Energy Solution. “We are fully committed to realizing our vision of leading the future green energy era with innovation in electrification for a sustainable battery ecosystem.”

“As one of the world’s largest battery manufacturers, LG Energy Solution is at the centre of what enables the transition to a net-zero economy. The company’s inclusion in the 2025 Global 100 is a testament to its global leadership,” said Toby Heaps, CEO of Corporate Knights.

About LG Energy Solution

LG Energy Solution (KRX: 373220), a split-off from LG Chem, is a leading global manufacturer of lithium-ion batteries for electric vehicles, mobility, IT, and energy storage systems. With 30 years of experience in revolutionary battery technology and extensive research and development (R&D), the company is the top battery-related patent holder in the world with over 58,000 patents. Its robust global network, which spans North America, Europe, and Asia, includes battery manufacturing facilities established through joint ventures with major automakers. Committed to building sustainable battery ecosystem, LG Energy Solution aims to achieve carbon neutrality across its value chain by 2050, while embodying the value of shared growth and promoting diverse and inclusive corporate culture. To learn more about LG Energy Solution’s ideas and innovations, visit https://news.lgensol.com.

Science and Technology Daily: AI for a Better Life

BEIJING, Jan. 22, 2025 /PRNewswire/ — As AI continues to evolve at an unprecedented pace, with breakthroughs in generative models, ethical guidelines, and applications across various sectors, the question is often asked — how will these advancements positively impact people’s daily life?

 

Science and Technology Daily: AI for a Better Life

 


Science and Technology Daily recently organized a panel discussion “Tech with Heart, AI for Good,” experts took a deep dive into the topic “AI for a Better Life.” They explored the transformative potential of AI, discussing its role in healthcare, traditional Chinese medicine (TCM), legal services, and beyond.

Hosted by Wu Baojun from the University of Chinese Academy of Sciences, two experts were invited: Chen Yingying, an associate researcher at the Institute of Automation of the Chinese Academy of Sciences, and Professor Gao Shaolin, an expert from Peking University Law and AI Research Center.

AI is revolutionizing healthcare

The discussion began with examples of how AI is revolutionizing healthcare, particularly in bridging the gap between urban and rural medical resources.

“By utilizing smart technology, the experience and knowledge of seasoned doctors can now be shared more widely, reaching remote villages and mountainous regions as well as community hospitals,” Chen said.

This democratization of quality medical care not only alleviates the shortage of primary-level medical staff but also improves diagnosis accuracy and efficiency through advanced image recognition technologies, such as those used in CT scans.

The application of AI in healthcare extends to TCM, which has been traditionally practiced based on centuries-old wisdom. Integrating AI into TCM could potentially make this ancient practice more accessible and accurate, thereby benefiting people globally.

TCM, described as an information science, relies on collecting various types of data through observation, listening, inquiry, and pulse-taking. Traditionally, it takes decades for TCM practitioners to accumulate enough experience to make accurate judgments.

“However, with AI, this process could be accelerated, making the wisdom of experienced TCM doctors accessible to everyone,” Professor Gao said.

He added that the integration of AI into TCM promises to improve preventive healthcare, allowing for early detection and intervention based on comprehensive health information analysis.

For instance, AI can analyze collected data like facial complexion, tongue coating, and pulse patterns to predict potential health issues before they manifest. This approach aligns with the TCM principle of “treating disease before it occurs,” which emphasizes prevention over cure. In this way, AI can help maintain public health by identifying risks and suggesting personalized preventative measures.

Legal services transformed by AI

AI is also transforming legal services. In the past, comprehending the vast body of laws, regulations, and statutes was a monumental task for legal professionals. Now, AI tools are being developed to organize legal knowledge, analyze disputes, and provide guidance on legal procedures.

Gao said these advancements not only promote legal education but also simplify court proceedings by simulating courtroom scenarios. As a result, trials can be more efficient, and many cases may reach agreements without debate, reducing the need for formal legal processes.

Furthermore, AI applications in contract review systems help prevent legal disputes by identifying potential points of contention before contracts are signed. This proactive approach ensures that contracts meet the true requirements of both parties, thereby minimizing conflicts during execution.

Additionally, AI can assist in finding similar case studies, providing individuals with a better understanding of legal procedures and enabling them to handle disputes more effectively. The use of AI in legal firms also opens up new career paths, combining computer science and law to create innovative solutions for complex legal challenges.

A future shaped by interdisciplinary collaboration

Looking ahead, both experts agreed that AI’s influence will permeate all industries and fields, acting as a super-large framework that integrates diverse disciplines.

From mathematics and physics to energy and humanities, AI has the potential to empower different academic and industrial developments. The future of AI lies in interdisciplinary collaboration, where professionals from computer science and AI join forces with domain experts in various sectors. Such collaborations will drive innovation, leading to new professions and opportunities.

For young people planning their educational paths, the advice is clear: embrace interdisciplinary learning, understand technological trends, and focus on developing skills in creativity and imagination—qualities that remain irreplaceable by AI.

Professor Gao emphasized that while some jobs might evolve or change due to AI, new opportunities would arise, particularly in areas requiring human interaction, creativity, and emotional intelligence.

AI products benefit all

The international cooperation in AI development was also discussed. Chen said that many Chinese companies are striving to “go global,” bringing excellent products developed within China’s complete industrial chain to the world, like the social-networking and video-sharing platform TikTok.

Professor Gao noted that with more countries joining the Belt and Road Initiative, cultural exchanges and AI collaborations are deepening. Chinese intelligent products going global bring in smart applications that promote local AI industry development, contributing to China’s vision of building a community with a shared future for humankind.

In essence, China’s fundamental attitude towards developing AI highlights mutual benefit and common development, thus making countries more willing to cooperate with it. China’s international collaboration in AI research aims to make joint efforts to improve people’s livelihood worldwide.

We can expect that as AI continues to evolve, it offers a tool for humanity to explore wider horizons, assisting in the discovery of fascinating aspects of the universe and ultimately contributing to better lives for current and future generations.

The discussion concluded with the hope that AI would become a collaborator rather than a competitor, aiding humans in achieving greater fulfillment and development, envisioning a world where AI and humans work together to overcome challenges and build a better tomorrow.

Lepu Biopharma has granted ArriVent Exclusive License for MRG007, a Potential Best-in-Class ADC for the treatment of Gastrointestinal Cancers

HONG KONG, Jan. 22, 2025 /PRNewswire/ — Today, Lepu Biopharma Co., Ltd (Stock Code: 02157.HK) announced that it has entered into an exclusive licensing agreement with ArriVent BioPharma, Inc. for MRG007, a Potential Best-in-Class antibody- drug conjugate (“ADC“) for the treatment of Gastrointestinal (“GI“) Cancers.

Under the terms of the agreement, Lepu Biopharma has granted ArriVent exclusive rights to develop, manufacture and commercialize MRG007 outside of Greater China which includes mainland China, Hong Kong, Macau and Taiwan. Lepu Biopharma will receive a one-time upfront and near-term milestone payments totaling $47 million in cash and is eligible to receive up to $1.16 billion in development, regulatory and sales milestones and tiered royalties on net sales outside of Greater China.

MRG007 has shown robust antitumor activity in preclinical models of GI cancers and a favorable therapeutic index based on IND enabling studies. The first IND submission is planned for the first half of 2025 with an initial clinical development focus in colorectal, pancreatic and other GI cancers.

Sui Ziye Ph.D., Executive Director and Chief Executive Officer of Lepu Biopharma said, “We are very pleased to be working with ArriVent. Lepu Biopharma has been dedicated to promoting the technological advancement of innovative ADCs in China. We believe MRG007 is one of our potential best-in-class ADC molecules in pre-clinical stage. The agreement is a recognition of our self-dependent R&D capabilities. We look forward to collaborating with ArriVent to advance the development of MRG007 globally and help bring this potential promising therapy to more patients around the world.”

Bing Yao, Chairman and Chief Executive Officer of ArriVent said ,” We believe MRG007 is a potential best-in-class ADC for the treatment of GI malignancies based on preclinical and IND enabling studies. Expanding our pipeline with MRG007 furthers our mission to develop novel medicines for cancers with high unmet needs worldwide and accelerates our ADC portfolio by adding a program which plans to enter the clinic in the near-term. We look forward to collaborating with Lepu Biopharma in advancing this program globally.”

About Lepu Biopharma Co., Ltd.

Lepu Biopharma Co., Ltd. (Stock Code: 02157.HK) is an innovation-driven company focusing on oncology therapeutics, in particular, targeted therapy and oncology immunotherapy, with a strong China foundation and global vision. The company is dedicated to developing innovative ADCs through its advanced ADC technology platform. Lepu Biopharma highly values the continuing build-out of its own commercialization capabilities and is determined to pursue the goal towards strong transformation from core technology to drugs and industrialization. At present, the product pipeline of Lepu Biopharma covers three major areas, namely immunotherapies, ADC targeted therapies and oncolytic virus drugs, including one clinical/commercialization- stage drug candidate, seven clinical-stage drug candidates (six of which are ADC drug candidates) and three clinical-stage combination therapies of the key candidates in its pipeline. The company houses the leading ADC drug candidate pipeline in China.

About ArriVent

ArriVent is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. ArriVent seeks to utilize its team’s deep drug development experience to maximize the potential of its lead development candidate, firmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization.